Previous 10 | Next 10 |
Jounce Therapeutics (NASDAQ: JNCE ): Q1 GAAP EPS of -$0.78 misses by $0.21 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – – Ended the quarter with $148.6 million in cash, cash equ...
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2020 financial result...
Introduction Jounce Therapeutics ( JNCE ) is a clinical-stage immunotherapy company developing therapies that enable the immune system to attack tumors. The company has developed a suite of integrated technologies that comprise their Translational Science Platform, enabling them to compr...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Intro & pipeline Agenus ( AGEN ) is an immuno-oncology ((IO)) company with a deep and diversified pipeline, a technology for novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing. Agenus believes that the...
Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...
Menlo Therapeutics (NASDAQ: MNLO ) initiated with Overweight rating and $8 (161% upside) price target at Barclays. More news on: Menlo Therapeutics Inc., Molecular Templates, Inc., Passage Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Image source: The Motley Fool. Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q4 2019 Earnings Call Feb 27, 2020 , 8:00 a.m. ET Operator Continue reading
Jounce Therapeutics, Inc. (JNCE) Q4 2019 Results Conference Call February 27, 2020 08:00 AM ET Company Participants Komal Joshi - Investor Relations Rich Murray - Chief Executive Officer & President Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...